Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod ...
Media Release Overall response rate (ORR) increases to 40.4%, according to iRECIST, in TACTI-002 all-comer PD-L1 Phase II trial in 1st line non-small cell lung cancer (1L NSCLC) ORR improved across all PD-L1 status groups by central assessment compared …